-
A network medicine approach to discover common novel drug target mechanisms across autoimmune diseases -
Scipher Medicine Strengthens Leadership Team with Appointment of Sam A Davis, JD as General Counsel -
Scipher Medicine Welcomes John Strumbos as Chief Financial Officer -
Scipher Medicine Welcomes Chip Parkinson as Chief Commercial Officer of its Diagnostics Business -
Ventegra Partners with Scipher Medicine For Patient-Centric Approach To Improve Outcomes and Lower Costs for Rheumatoid Arthritis Care -
A molecular signature response classifier stratifies seropositive rheumatoid arthritis patients based on their likelihood of inadequate response to TNF inhibitor therapies -
Molecular Test Further Helps Personalize Rheumatoid Arthritis Care -
New Partnership Delivers Precision Medicine to Pharmacy Benefits Managers - Can a Blood-Based Test Predict TNFi Nonresponse in RA?
- In RA, New Molecular Signature Test Confirms Who Won’t Respond to Anti-TNF Therapy During Any Point in Therapeutic Journey
- Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients
-
Scipher Medicine Introduces Breakthrough Capability to Accelerate Drug Discovery -
Scipher Medicine Translates Complex Biology to Predict Better Outcomes -
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class, TNFi -
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test